Plus, news about Abilita Therapeutics, Orion, Novartis, XGEN Venture, Palleon, Henlius, TigaTx, HERVolution Therapeutics and Krystal Biotech: ...

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics Orion Corporation ("Orion") and Abilita Therapeutics ...

Risk intelligence platform sees 3x revenue growth as the surge in sophisticated fraud attacks drive demand for AI-powered ...

ORION CORPORATION PRESS RELEASE 18 DECEMBER 2024 at 17.00 EET Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics ...

Abilita Therapeutics, Inc. ("Abilita") today announced a global licensing and multi-target research collaboration with Finnish Orion Corporation ("Orion") focused on the discovery, development and ...

Vir Biotechnology Inc. today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at ...

Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the selection of eosinophilic esophagitis (EoE) as its ...

Applied Therapeutics shares (NASDAQ:APLT) were down 75% early Friday, the first trading session after the company announced the FDA had declined to approve its drug govorestat for the treatment of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report), Madrigal Pharmaceuticals (MDGL – Research Report ...

NEW YORK - Applied Therapeutics Inc . (NASDAQ:APLT), a biopharmaceutical company, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company, today announced preliminary topline results from its NORSE EIGHT clinical trial, which evaluated ONS-5010 for the treatment ...